TECH
NEUTRAL
$60.58
Live
Bio-Techne Corporation · NASDAQ
Target $72.27
(+19.3%)
$46.05
52W Range
$72.16
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 21, 2026
Market cap
$9.48B
P/E
114.3
ROE
4.0%
Profit margin
6.7%
Debt/Equity
0.17
Dividend yield
0.53%
AI Analysis
AI-powered fundamental assessment
Confidence
80%
Bio-Techne exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.17. However, there is a massive disconnect between the current price ($60.58) and deterministic value metrics, such as the Graham Number ($12.40) and Intrinsic Value ($10.94). While the PEG ratio of 0.76 and forward P/E of 27.99 suggest growth potential that justifies a premium, stagnant revenue growth (-0.40%) and bearish technical trends temper the outlook. The stock is a high-quality company trading at a significant growth premium.
Key Strengths
Strong financial health indicated by Piotroski F-Score of 8/9
Excellent liquidity with a Current Ratio of 4.54
Very low leverage (Debt/Equity 0.17)
Attractive PEG ratio (0.76) suggesting undervaluation relative to growth
Consistent earnings growth (9.10% YoY) despite flat revenue
Key Risks
Extreme valuation premium over Graham and Intrinsic value estimates
Stagnant top-line growth (Revenue Growth -0.40%)
Bearish technical trend (0/100) and negative long-term price performance
Bearish insider sentiment with net selling activity
High trailing P/E ratio (114.30) creating vulnerability to earnings misses
AI Fair Value Estimate
Based on comprehensive analysis
$64.12
+5.8% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
53
Moderate
30
55
45
95
40
AI Verdict
High-quality asset with valuation concerns
Key drivers: Piotroski F-Score, PEG Ratio, Revenue Stagnation, Valuation Gap
Confidence
85%
Value
30/100
Ref P/E 114.30, PEG 0.76, Graham Number $12.4
Positives
- PEG ratio < 1.0
Watchpoints
- Price significantly exceeds Graham Number
- Trailing P/E is extremely high
Future
55/100
Ref Growth rates: Rev -0.40%, EPS +9.10%
Positives
- Positive EPS growth
- Bullish analyst target price ($72.27)
Watchpoints
- Negative YoY and Q/Q revenue growth
Past
45/100
Ref Historical price trends
Positives
- Strong 1-year recovery (+28.2%)
Watchpoints
- Poor 5-year performance (-41.6%)
- Poor 3-year performance (-26.4%)
Health
95/100
Ref Piotroski F-Score, Debt/Equity 0.17
Positives
- Piotroski F-Score 8/9
- Very low Debt/Equity
- High Current/Quick ratios
Watchpoints
No urgent risks highlighted.
Dividend
40/100
Ref Yield 0.53%, Payout 60.38%
Positives
- Consistent payout
Watchpoints
- Very low yield (0.53%)
- Moderate payout ratio (60.38%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$60.58
Analyst Target
$72.27
Upside/Downside
+19.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TECH and closest competitors.
Updated 2026-04-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TECH
Bio-Techne Corporation
Primary
|
-41.6% | -26.4% | +28.2% | -2.9% | +17.7% | +5.3% |
|
AXSM
Axsome Therapeutics, Inc.
Peer
|
+146.1% | +162.6% | +79.0% | +84.4% | +21.0% | +4.9% |
|
MASI
Masimo Corporation
Peer
|
-25.5% | -6.9% | +16.2% | +20.6% | +1.7% | -0.0% |
|
BIO-B
Bio-Rad Laboratories, Inc.
Peer
|
-47.0% | -22.7% | -10.4% | +26.6% | +0.7% | +0.7% |
|
ICLR
ICON Public Limited Company
Peer
|
-43.0% | -45.5% | -19.8% | -38.0% | +19.4% | +9.3% |
TEC
Bio-Techne Corporation
Primary
5Y
-41.6%
3Y
-26.4%
1Y
+28.2%
6M
-2.9%
1M
+17.7%
1W
+5.3%
AXS
Axsome Therapeutics, Inc.
Peer
5Y
+146.1%
3Y
+162.6%
1Y
+79.0%
6M
+84.4%
1M
+21.0%
1W
+4.9%
MAS
Masimo Corporation
Peer
5Y
-25.5%
3Y
-6.9%
1Y
+16.2%
6M
+20.6%
1M
+1.7%
1W
-0.0%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-47.0%
3Y
-22.7%
1Y
-10.4%
6M
+26.6%
1M
+0.7%
1W
+0.7%
ICL
ICON Public Limited Company
Peer
5Y
-43.0%
3Y
-45.5%
1Y
-19.8%
6M
-38.0%
1M
+19.4%
1W
+9.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
114.3
Forward P/E
27.99
PEG Ratio
0.76
P/B Ratio
4.7
P/S Ratio
7.8
EV/Revenue
7.94
EV/EBITDA
29.19
Market Cap
$9.48B
Profitability
Profit margins and return metrics
Profit Margin
6.67%
Operating Margin
19.67%
Gross Margin
66.61%
ROE
3.97%
ROA
6.52%
Growth
Revenue and earnings growth rates
Revenue Growth
-0.4%
Earnings Growth
+9.1%
Q/Q Revenue Growth
-0.39%
Q/Q Earnings Growth
+8.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.17
Low debt
Current Ratio
4.54
Strong
Quick Ratio
2.59
Excellent
Cash/Share
$1.15
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.3B
Gross Margin
64.6%
Op. Margin
18.4%
Net Margin
12.8%
Total Assets
$2.5B
Liabilities
$0.5B
Equity
$2.0B
Debt/Equity
0.25x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
93%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-04
$0.46
+5.8% surprise
2025-11-05
$0.24
-4.0% surprise
2025-08-06
$0.53
+5.8% surprise
Healthcare Sector Comparison
Comparing TECH against 498 companies in the Healthcare sector
(28 bullish, 153 neutral, 317 bearish)
P/E Ratio
114.3
This Stock
vs
84.2
Sector Avg
+35.8%
(Expensive)
Return on Equity (ROE)
3.97%
This Stock
vs
-95.47%
Sector Avg
-104.2%
(Below Avg)
Profit Margin
6.67%
This Stock
vs
-15.87%
Sector Avg
-142.0%
(Weaker)
Debt to Equity
0.17
This Stock
vs
2.89
Sector Avg
-94.0%
(Less Debt)
Revenue Growth
-0.4%
This Stock
vs
137.48%
Sector Avg
-100.3%
(Slower)
Current Ratio
4.54
This Stock
vs
4.66
Sector Avg
-2.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TECH
Bio-Techne Corporation
|
NEUTRAL | $9.48B | 114.3 | 4.0% | 6.7% | $60.58 | |
|
AXSM
Axsome Therapeutics, Inc.
|
BEARISH | $9.37B | - | -275.5% | -40.9% | $185.96 | Compare |
|
MASI
Masimo Corporation
|
BEARISH | $9.35B | 46.6 | 23.4% | -9.9% | $178.47 | Compare |
|
BIO-B
Bio-Rad Laboratories, Inc.
|
BEARISH | $9.79B | - | -9.5% | -26.4% | $312.75 | Compare |
|
ICLR
ICON Public Limited Company
|
NEUTRAL | $9.06B | 15.7 | 6.3% | 7.4% | $116.5 | Compare |
TECH
Bio-Techne Corporation
NEUTRAL
Mkt Cap
$9.5B
P/E
114.3
ROE
4.0%
Price
$60.58
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-14 | KELDERMAN KIM | Chief Executive Officer | Option Exercise | 36,500 | $1,737,400 |
| 2026-04-02 | BOHNEN SHANE | General Counsel | Stock Award | 2,259 | - |
| 2026-02-17 | HERR AMY E. | Director | Sale | 1,976 | $116,791 |
| 2026-02-03 | HERR AMY E. | Director | Stock Award | 38 | - |
| 2026-01-30 | MCMANUS MATTHEW F | Officer | Stock Award | 4,621 | - |
| 2025-11-03 | HIPPEL JAMES | Chief Financial Officer | Stock Award | 24,704 | - |
| 2025-11-03 | GEIST WILLIAM | Officer | Stock Award | 9,911 | - |
| 2025-10-30 | HIGGINS JOHN L | Director | Stock Award | 1,640 | - |
| 2025-10-30 | KEEGAN JOSEPH D | Director | Stock Award | 1,640 | - |
| 2025-10-30 | BAUMGARTNER ROBERT V | Director | Stock Award | 1,640 | - |
| 2025-10-30 | BUSHMAN JULIE L. | Director | Stock Award | 1,640 | - |
| 2025-10-30 | VESSEY RUPERT J | Director | Stock Award | 1,640 | - |
| 2025-10-30 | SETH ALPNA | Director | Stock Award | 1,640 | - |
| 2025-10-30 | KLIMOVSKY JUDITH V | Director | Stock Award | 1,640 | - |
| 2025-10-30 | HERR AMY E. | Director | Stock Award | 1,640 | - |
KELDERMAN KIM
Chief Executive Officer
2026-04-14
36,500 shares
·
$1,737,400
BOHNEN SHANE
General Counsel
2026-04-02
2,259 shares
HERR AMY E.
Director
2026-02-17
1,976 shares
·
$116,791
HERR AMY E.
Director
2026-02-03
38 shares
MCMANUS MATTHEW F
Officer
2026-01-30
4,621 shares
HIPPEL JAMES
Chief Financial Officer
2025-11-03
24,704 shares
GEIST WILLIAM
Officer
2025-11-03
9,911 shares
HIGGINS JOHN L
Director
2025-10-30
1,640 shares
KEEGAN JOSEPH D
Director
2025-10-30
1,640 shares
BAUMGARTNER ROBERT V
Director
2025-10-30
1,640 shares
BUSHMAN JULIE L.
Director
2025-10-30
1,640 shares
VESSEY RUPERT J
Director
2025-10-30
1,640 shares
SETH ALPNA
Director
2025-10-30
1,640 shares
KLIMOVSKY JUDITH V
Director
2025-10-30
1,640 shares
HERR AMY E.
Director
2025-10-30
1,640 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
10-Q
8-K
10-Q
DEF 14A
10-K
8-K
10-Q
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
11 analysts
Evercore ISI Group
2026-04-06
In-Line
In-Line
Wells Fargo
2026-02-06
Overweight
Overweight
Citigroup
2026-02-05
Buy
Buy
Stifel
2026-02-05
Hold
Hold
TD Cowen
2026-02-05
Buy
Buy
UBS
2026-02-05
Buy
Buy
Evercore ISI Group
2026-02-05
In-Line
In-Line
Evercore ISI Group
2026-01-05
Outperform
In-Line
Argus Research
2025-11-20
Buy
Buy
UBS
2025-11-06
Buy
Buy
Past News Coverage
Recent headlines mentioning TECH from our newsroom.
Newest → oldest
No matching news yet.